Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) CFO Sells $21,531,075.00 in Stock

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) CFO Ian F. Smith sold 133,750 shares of the firm’s stock in a transaction dated Friday, July 21st. The stock was sold at an average price of $160.98, for a total value of $21,531,075.00. Following the completion of the transaction, the chief financial officer now owns 151,738 shares of the company’s stock, valued at $24,426,783.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Vertex Pharmaceuticals Incorporated (NASDAQ VRTX) traded down 0.28% on Friday, hitting $148.13. The stock had a trading volume of 887,138 shares. Vertex Pharmaceuticals Incorporated has a one year low of $71.46 and a one year high of $167.85. The stock has a market cap of $37.35 billion, a P/E ratio of 142.30 and a beta of 1.77. The company’s 50-day moving average is $146.73 and its 200-day moving average is $117.81.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.39 EPS for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.33. Vertex Pharmaceuticals had a return on equity of 4.64% and a net margin of 12.05%. The business had revenue of $544.10 million during the quarter, compared to the consensus estimate of $489.95 million. During the same period last year, the firm earned $0.24 earnings per share. The company’s revenue for the quarter was up 26.1% compared to the same quarter last year. On average, analysts anticipate that Vertex Pharmaceuticals Incorporated will post $1.60 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) CFO Sells $21,531,075.00 in Stock” was published by BNB Daily and is the sole property of of BNB Daily. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://www.baseball-news-blog.com/2017/08/19/ian-f-smith-sells-133750-shares-of-vertex-pharmaceuticals-incorporated-nasdaqvrtx-stock-updated-updated-updated.html.

Institutional investors have recently modified their holdings of the stock. Korea Investment CORP increased its position in shares of Vertex Pharmaceuticals by 225.3% in the first quarter. Korea Investment CORP now owns 950 shares of the pharmaceutical company’s stock worth $104,000 after buying an additional 658 shares during the last quarter. Guardian Life Insurance Co. of America increased its position in shares of Vertex Pharmaceuticals by 0.6% in the first quarter. Guardian Life Insurance Co. of America now owns 956 shares of the pharmaceutical company’s stock worth $105,000 after buying an additional 6 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its position in shares of Vertex Pharmaceuticals by 15.4% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 988 shares of the pharmaceutical company’s stock worth $127,000 after buying an additional 132 shares during the last quarter. FNY Partners Fund LP increased its position in shares of Vertex Pharmaceuticals by 900.0% in the second quarter. FNY Partners Fund LP now owns 1,000 shares of the pharmaceutical company’s stock worth $128,000 after buying an additional 900 shares during the last quarter. Finally, FUKOKU MUTUAL LIFE INSURANCE Co increased its position in shares of Vertex Pharmaceuticals by 7.1% in the first quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 1,500 shares of the pharmaceutical company’s stock worth $164,000 after buying an additional 100 shares during the last quarter. Institutional investors own 94.89% of the company’s stock.

Several brokerages recently weighed in on VRTX. Maxim Group set a $195.00 price target on Vertex Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, July 27th. J P Morgan Chase & Co set a $184.00 price target on Vertex Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, July 27th. Oppenheimer Holdings, Inc. lifted their price target on Vertex Pharmaceuticals from $150.00 to $175.00 and gave the company an “outperform” rating in a research report on Thursday, July 27th. Morgan Stanley reiterated an “overweight” rating and set a $190.00 price target (up from $153.00) on shares of Vertex Pharmaceuticals in a research report on Saturday, July 22nd. Finally, Vetr cut Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $181.00 price target for the company. in a research report on Monday, July 24th. Five investment analysts have rated the stock with a hold rating, twenty-two have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $162.88.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply